Consolidated Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Net product sales	$ 70,692,027	$ 37,074,567	$ 6,089,306
Revenues from royalties	4,453,707	4,200,506	4,406,589
Revenues from research grant services	220,150
Total revenues	75,365,884	41,275,073	10,495,895
Operating expenses:
Cost of product sales	4,002,303	2,120,221	445,980
Cost of research grant services	147,431
Research and development	49,506,199	23,066,037	15,253,739
Selling and marketing	63,201,776	52,463,409	38,140,558
General and administrative	29,934,875	22,027,587	17,285,033
Total operating expenses	146,792,584	99,677,254	71,125,310
Loss from operations	(71,426,700)	(58,402,181)	(60,629,415)
Other income (expense):
Interest income	51,914	42,815	38,785
Interest expense	(4,097,846)	(1,385,342)
Other, net	(31)	4,081	(37,733)
Loss before provision for income taxes	(75,472,663)	(59,740,627)	(60,628,363)
Provision for income taxes	3,200	3,200	3,200
Net loss	$ (75,475,863)	$ (59,743,827)	$ (60,631,563)
Basic and diluted net loss per share	$ (0.53)	$ (0.45)	$ (0.51)
Basic and diluted weighted average number of common shares outstanding	142,269,399	133,358,571	119,405,230